QL1706 Plus Anlotinib as a Later-line Treatment for Patients With Advanced Lung Cancer

NCT07636226 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

NOT_YET_RECRUITING

Status

120

Enrollment

OTHER

Sponsor class

Conditions

Small Cell Lung Cancer

Interventions

DRUG: QL1706
DRUG: Anlotinib

Sponsor

Sun Yat-sen University